State of Research
Quality of Conclusions
TBD Papers studying this directly
TBD Companies working on this
Access all our research
Become a free member now to get unlimited access.
Receive our weekly update on the latest psychedelic research, make (private) notes on pages, and download our reports.
Our vision is that psychedelics can be used worldwide to better the lives of as many as 450 million people who suffer from mental health problems. Our information hopes to make that vision come to life just a little faster.
Eating Disorders Research
Here will be a narrative, readable, summary of the research.
In our literature study we came across the following studies of note. Browse the meta, review, commentary articles for an overview. Check out the individual studies for specific experiments and observations.
Registered clinical studies investigating psychedelic drugs for psychiatric disorders
2021 | Gill, H., Lipsitz, O., Lui, L. M. W., McIntyre, R. S., Rosenblat, J. D., Siegel, A. N., Teopiz, K. M.
This review (2021) summarizes the study characteristics of all ongoing registered clinical trials investigating psychedelic drugs for psychiatric disorders and identifies that their majority focuses on investigating MDMA and psilocybin for treating depression or PTSD, while only 30% of their results are published.
The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD
2020 | Brewerton, T. D., Lafrance, A., Mithoefer, M. C.
This hypothesis paper (2020) makes the case for treating eating disorders (EDs) comorbid with posttraumatic stress disorder (PTSD).
Perspectives on psychedelic treatment and research in eating disorders: a web-based questionnaire study of people with eating disorders
2021| Harding, F., Himmerich, H., Kan, C., Keeler, J., Seynaeve, M., Treasure, J.
This survey study (n=200) examined the views of people with eating disorders (EDs) with regards to psychedelic therapy. Over half of the respondents said they would take part in psychedelic research while 60% believed it is worthwhile continuing research in this area. Respondents agreed that education is needed surrounding psychedelics and that therapy should take place in a professional setting.
Psilocybin in the treatment of anorexia nervosa: The English transition of a French 1959 case study
2021| Spriggs, M. J., Verroust, V., Zafar, R.
In this case study (n=1) the authors revisit the first known documented case of psilocybin being used to treat anorexia nervosa. After two separate injections of psilocybin, the patient stated she was able to understand the psychological cause of her illness. With clinical trials now underway exploring the effects of psychedelics on eating disorders, this case study offers interesting insight.
Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics
2018| Kuypers, K. P. C., Mason, N. L.
The observational survey study (n=1,967) investigated the frequency and efficacy of self-medication practices amongst psychedelic users and found that the prevalence of lifetime psychopathologies amongst psychedelic users was higher than in the general population. Although psychedelics were seldom used for self-medication, those who did use psychedelics in this manner reported it to be more effective than the current lines of treatment for mental illness.
Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa
2021| Aouad, P., Maguire, S., McGregor, I. S., Rodan, S.
This review (2021) appraises psilocybin as a novel pharmacotherapy for treatment-resistant anorexia nervosa (AN). It observes that classic psychedelics like LSD, 5-MeO-DMT, DMT, and psilocybin show a significant decrease in anxiety and depression-like symptoms, and lasting improvement in mental health. The review suggests that classic psychedelics, psilocybin in particular, show promise in normalizing dysfunctional neurobiological systems in AN and point towards a novel treatment intervention for treatment-resistant patients.
Ketamine Use for Suicidal Ideation in the General Hospital: Case Report and Short Review
2018| Baup, E., Lefebvre, D., Lemogne, C., Limosin, F., Passeron, A., Rieutord, M., Seigneurie, A. S., Thauvin, I., Vulser, C., Vulser, H.
This case report (n=1) describes an anorexic patient who was treated with repeated dose ketamine (0.5mg/kg, 20mg) following a suicide attempt and persevering suicidal ideation (SI). Although the first dose had little effect, the second dose administered 2 weeks after led to a dramatic decrease in depression, hopelessness, and suicidal ideation.
An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders
2018| Files, N., Fletcher, J., Lafrance, A., Loizaga-Velder, A., Renelli, M., Tupper, K. W.
This interview study (n=13) suggests that ayahuasca could be an effective therapeutic tool for eating disorders (EDs). Themes identified were 1) rapid reduction in ED thoughts and symptoms, 2) healing at the perceived root cause, 3) help process painful feelings and memories, 4) greater self-love and self-acceptance, and 5) activated spiritual elements of healing.
Nourishing the spirit: exploratory research on ayahuasca experiences along the continuum of recovery from eating disorders
2017| Files, N., Fletcher, J., Lafrance, A., Loizaga-Velder, A., Renelli, M., Tupper, K. W.
This interview study (n=16) suggests that ayahuasca may hold promise as a treatment for eating disorders (EDs). The interviewees (who used ayahuasca) indicated shifts in body perception, reduction or cessation of ED and mental health symptoms.
Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder
2020| Carhart-Harris, R. L., Kettner, H., Spriggs, M. J.
This prospective survey study (n=28) found significant improvements on depression and well-being scores after psychedelics use for those with eating disorders (EDs).
This section compares the research with psychedelics to other therapies, medicines, or treatments.
This section highlights the various measures used and their use in research.
Who are the top researches in this area, the ones who have done the groundbreaking research.
What do we not know at this time? Where are the gaps in our knowledge and are we closing it?
The companies that are actively engaged in researching this topic or (planning to) provide therapy focussed on this topic.
This section highlights everything done outside of academia, from popular press to books and non academic research.